Dabigatran Etexilate for Secondary Stroke Prevention in Patients With Embolic Stroke of Undetermined Source (RE-SPECT ESUS)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 5390 participants.
Also called NCT02239120
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose prevention
- Phase
- Phase 3
- Enrolled
- 5,390 participants
- Sponsor
- Registry
-
NCT02239120 -
2013-003444-24
-
- Other papers using this trial's data
- Antithrombotic Treatment of Embolic Stroke of Undetermined Source: RE-SPECT ESUS Elderly and Renally Impaired Subgroups
- Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source
- Dabigatran or Aspirin After Embolic Stroke of Undetermined Source in Patients With Patent Foramen Ovale: Results From RE-SPECT ESUS
- Dabigatran or Aspirin in East Asian Patients With Embolic Stroke of Undetermined Source: RE-SPECT ESUS Subgroup Analysis
- Predictors of Atrial Fibrillation Development in Patients With Embolic Stroke of Undetermined Source: An Analysis of the RE-SPECT ESUS Trial
- Predictors of Recurrent Stroke After Embolic Stroke of Undetermined Source in the RE-SPECT ESUS Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Croatia, Czechia, Estonia, France, Germany, Greece, Hong Kong SAR China, Hungary, India, Israel, Italy, Japan, Malaysia, Mexico, New Zealand, Peru, Poland, Portugal, Russia, Serbia, Singapore, Slovakia, Slovenia, South Africa, South Korea, Spain, Sweden, Switzerland, Taiwan, Thailand, Türkiye, Ukraine
- Registry status
- Completed
Technical summary
Registry record NCT02239120. Randomized; double masking; primary purpose prevention. Start 2014-11-27 (actual); primary completion 2018-08-14 (actual). Results posted on 2019-09-06.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Dabigatran Etexilate for Secondary Stroke Prevention in Patients With Embolic Stroke of Undetermined Source (RE-SPECT ESUS)
- Condition
- Stroke
- Condition
- Secondary Prevention
- Intervention (Drug)
- optional ASA as comedication
- Intervention (Drug)
- placebo to ASA
- Intervention (Drug)
- placebo to optional ASA as comedication
- Intervention (Drug)
- placebo to dabigatran etexilate
- Intervention (Drug)
- ASA 100 mg
- Intervention (Drug)
- dabigatran etexilate
- Lead sponsor
- Boehringer Ingelheim
Record details
- Record id
cardio:ct-nct02239120- Content hash
0d0c1dfbcc2377466dd53637d89a059207801b14ee0fe2ae074249445a84cbb2